Role of induction chemotherapy in invasive cervical cancer

Abstract

The 386 cases of invasive cervical carcinoma treated with radiotherapy atone were statistically analyzed to delineate the high risk factors (HRFs) associated with a significantly high treatment failure rate; they were (1) stages III–IV, (2) lesion ≥4.0 cm, (3) small cell carcinoma or adenocarcinoma, (4) stages I–II with lesion ≥4.0 cm, and (5) lymphographic evidence of nodal metastasis. Then, chemoradiotherapy (induction chemotherapy plus subsequent radiotherapy) was instituted to 113 invasive cervical carcinoma patients with at least one such HRF. Each patient received two to three cycles of induction chemotherapy at about 3-week intervals. For squamous cell carcinoma, cisplatin, 100 mg/m 2 iv, was followed immediately by 5-fluorouracil, 1000 mg/m 2, as a 24-hr iv infusion × 5 days. For adenocarcinoma, cisplatin, 70 mg/m 2 iv, on Day 1 was followed by cytoxan, 250 mg/m 2, on Day 2, and adriamycin, 45 mg/m 2, on Day 3. Five-year survival of these patients according to each HRF, in the above order, was 69.1, 67.2, 68.1, 78.3, and 79.5% after chemoradiotherapy, all significantly higher than 57.4, 53.0, 54.5, 48.0, and 48.8% by radiotherapy alone. Drug toxicities such as leukopenia, hepatotoxicity, nephrotoxicity, and hypomagnesemia were seen in 46.5, 53.2, 47.1, and 55.4 % of all cycles, respectively. The toxicities altered drug schedule in 191 (61.2%) ongoing induction chemotherapy cycles. Our cisplatin-based induction chemotherapy is considered an effective preradiotherapy adjunct that can reduce treatment failure in HRF-associated invasive cervical Carcinoma.